Long-Term Outcomes and Mutation Profiling of Patients With Mantle Cell Lymphoma (MCL) Who Discontinued Ibrutinib

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.15567
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Improved Outcome for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL) Who Stop Ibrutinib +/− Rituximab for Reasons Other Than Progression of Disease

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma

Community Oncology
2013English

Combination of Ibrutinib With Rituximab (Ir) Is Highly Effective in Previously Untreated Elderly (>65 Years) Patients (Pts) With Mantle Cell Lymphoma (Mcl) - Phase Ii Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Ibrutinib Plus Palbociclib Has Efficacy in Mantle Cell Lymphoma

Cancer Discovery
Oncology
2019English

Differential Effects of BTK Inhibitors Ibrutinib and Zanubrutinib on NK Cell Effector Function in Patients With Mantle Cell Lymphoma

Haematologica
Hematology
2019English

Novel Chemotherapy-Free Combination Regimen for Ibrutinib-Resistant Mantle Cell Lymphoma

British Journal of Haematology
Hematology
2017English

Outcomes in First Relapsed-Refractory Younger Patients With Mantle Cell Lymphoma: Results From the Mantle-First Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Obinutuzumab Plus Ibrutinib in Relapse/Refractory Mantle Cell Lymphoma Patients: First Results of the Oasis Phase I Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy